What is the appropriate serum T threshold for medical “castration”?

For many years, the formal threshold level of serum testosterone (T) used to define medical “castration” has been < 50 ng/dl. However, it is widely recognized that this level is probably not low enough to accurately define a medically castrate state. … READ MORE …

Baseline serum androgen levels and responses to abiraterone acetate

Baseline levels of serum androgens were predictive for clinical response to treatment in the Phase III clinical trial of abiraterone acetate in men with chemotherapy-refractory, metastatic, castration-resistant prostate cancer (mCRPC), according to a new article in the Journal of Clinical Oncology. … READ MORE …

A very different way to project risk for clinically significant prostate cancer?

We don’t want to suggest that the recent paper by a Japanese research team in the journal Andrology is necessarily going to revolutionize the diagnosis of clinically significant prostate cancer. A great deal more work would be required to justify the hypothesis that they put forward. On the other hand, their hypothesis is definitely interesting. … READ MORE …

Better identification of potentially good responders to prostate cancer immunotherapy

A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others. … READ MORE …

Sexual function and serum T levels, before, on, and after 9 months of ADT

As many readers of this news service will be aware, good data on the recovery of libido and sexual function after a period of androgen deprivation therapy (ADT) are limited. We have long known that such recovery is variable, and we also know that it can take time, but sound data from a large cohort of patients has been “missing in action,” so to speak. A new paper by Ng et al. has now remedied this problem. … READ MORE …

Recovery of serum T levels after short-term LHRH agonist therapy

An article in the June issue of the Canadian Urological Association Journal offers preliminary evidence from a randomized clinical trial that men treated for 6 months with a short-acting LHRH agonist may recover normal serum testosterone (T) levels faster than those treated for the same time with a long-acting LHRH agonist. … READ MORE …

Testosterone replacement therapy in men with low serum T and untreated prostate cancer

An article in the May issue of BJU International has proposed establishment of an international data registry as being “the quickest way” to establish basic data on the risks related to testosterone replacement therapy in men with untreated prostate cancer. … READ MORE …

Castrate serum T levels and prostate cancer-specific mortality

A few weeks ago, a Letter to the Editor in the New England Journal of Medicine focused on the significance of castrate levels of serum testosterone (serum T) in men being treated with LHRH agonists for advanced forms of prostate cancer. … READ MORE …

Assessment of serum T levels in men on androgen deprivation therapy

A paper in a forthcoming issue of European Urology recommends strongly that clinicians should monitor serum testosterone (serum T) levels during androgen-deprivation therapy (ADT) in men with prostate cancer. … READ MORE …

T. vaginalis and prostate cancer risk

And in a report in the Los Angeles Times “Booster Shots” blog, “Men who are infected with the sexually transmitted bacterium Trichomonas vaginalis have a slightly increased risk of developing prostate cancer and double the normal risk of developing the aggressive form of the disease that spreads throughout the body.” … READ MORE …

Serum calcium levels and prostate cancer risk

In yet another example of the “maybe or maybe not” world of what helps to trigger increased risk for prostate cancer, we can now place serum calcium levels. Some recent studies (e.g., Skinner and Schwartz) have suggested an association between high levels of serum calcium and a high risk of prostate cancer death. Now an analysis of historical specimens from a large Swedish database suggests that there is no reason to believe that there is any association between serum calcium and prostate cancer risk. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers